Invesco’s Nuvectis Pharma NVCT Stock Holding History

Invesco’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.89M	Buy	+89,302	New	+$1.88M	﹤0.01%	2597

Other funds holding NVCT

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Invesco's NVCT Position: Q3 2026 in Review

Invesco opened a new position in Nuvectis Pharma (NVCT) in Q3 2026: 89,302 shares worth $1.89M. The stake represents ﹤0.01% of the portfolio and ranks #2597 among its holdings.

51 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

Invesco held 89,302 shares of Nuvectis Pharma worth $1.89M as of Q3 2026.
Nuvectis Pharma was a new Invesco position in Q3 2026.
Nuvectis Pharma made up ﹤0.01% of Invesco's portfolio in Q3 2026, its #2597 holding.
51 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Invesco's 13F filing for Q3 2026, filed 12 Nov 2026.